Radiprodil is primarily investigated for its potential therapeutic applications in the field of neurology, particularly in the treatment of neurological disorders. It functions as a selective antagonist of the NR2B subunit of the NMDA receptor, which plays a critical role in synaptic plasticity and memory function. By modulating this receptor, Radiprodil has shown promise in preclinical studies for alleviating symptoms associated with conditions such as chronic pain, epilepsy, and neurodegenerative diseases like Alzheimer's. Additionally, its neuroprotective properties are being explored for potential use in stroke recovery, where it may help reduce neuronal damage caused by excessive glutamate release. Research is ongoing to further understand its efficacy and safety in clinical settings.